An apolipoprotein B100 mimotope prevents obesity in mice

Hyo Joon Kim, Hee Jong Lee, Jung Soon Choi, Jemin Han, Ji Young Kim, Hyun Kyun Na, Hae Jung Joung, Young Sik Kim, Bert Binas

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Although apolipoprotein B100 (ApoB100) plays a key role in peripheral fat deposition, it is not considered a suitable therapeutic target in obesity. In the present study we describe a novel ApoB100 mimotope, peptide pB1, and the use of pB1-based vaccine-like formulations (BVFs) against high-fat diet (HFD)-induced obesity. In HFD- compared with chow-fed adolescent mice, BVFs reduced the 3-month body-weight gains attributable to increased dietary fat by 44-65 %, and prevented mesenteric fat accumulation and liver steatosis. The body-weight reductions paralleled the titres of pB1-reactive immunoglobulin G (IgG) antibodies, and pB1-reactive antibodies specifically recognized native ApoB100 and a synthetic peptide from the C-terminal half of ApoB100. In cultured 3T3L1 adipocytes, anti-pB1 antibodies increased lipolysis and inhibited low-density lipoprotein (LDL) uptake. In cultured RAW 264.7 macrophages, the same antibodies enhanced LDL uptake (without causing foam cell formation). These findings make ApoB100 a promising target for an immunization strategy against HFD-induced obesity.

Original languageEnglish
Pages (from-to)105-116
Number of pages12
JournalClinical Science
Volume130
Issue number2
DOIs
Publication statusPublished - 2016

Keywords

  • ApoB100
  • High-fat-diet-induced obesity
  • Humoral immunity
  • Mimotope

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'An apolipoprotein B100 mimotope prevents obesity in mice'. Together they form a unique fingerprint.

Cite this